WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be available for replay following the conference call. Individuals ...

Company Overview - Zimmer Biomet Holdings Inc (NYSE: ZBH) is a prominent player in the Health Care Equipment Industry [1] - The company is strategically expanding its product portfolio, which could potentially alter its revenue growth trajectory [1] - Zimmer Biomet remains liquid and is well-positioned to execute its strategic initiatives [1] Industry Context - The Health Care Equipment Industry is a dynamic sector with significant growth potential [1] - Companies in this industry are focusing on product portfolio expansion to drive revenue growth [1] Strategic Initiatives - Zimmer Biomet is actively working on expanding its product offerings, which is a key strategy to enhance its market position [1] - The company's liquidity position supports its ability to invest in strategic growth initiatives [1]

Core Viewpoint - Zimmer Biomet is experiencing growth driven by strategic product launches and market expansion, particularly in emerging markets, despite facing macroeconomic challenges and operational pressures [2][8][9]. Group 1: Revenue Growth and Market Expansion - Strong revenue growth in emerging markets, particularly in the Asia Pacific region, is a key driver for Zimmer Biomet [2]. - The company is on a diversification journey with its S.E.T. business, expecting mid-single-digit sales growth to continue into 2025 and 2026 [3]. - Zimmer Biomet's international business exceeded sales expectations in the third quarter, supported by strong demand in reconstructive knees, hips, and S.E.T. categories [18]. Group 2: Product Launches and Market Share - The company anticipates significant market share gains from upcoming product launches, including the Oxford Partial cementless Knee and Z1 HAMMR in Europe [10]. - Zimmer Biomet has been witnessing strong market share gains in reconstructive knees and hips across key geographies [18]. Group 3: Financial Performance and Challenges - In the third quarter of 2024, Zimmer Biomet's net sales were negatively impacted by foreign exchange rates, with an expected adverse impact of 75 basis points for the full year [15]. - The company faced a 3.9% increase in the cost of products sold and a 3.1% rise in selling, general, and administrative expenses, leading to a contraction in adjusted gross and operating margins [12]. - Staffing shortages, supply chain issues, and geopolitical complications are creating significant pressure on revenues and operating profit [17].

Company Overview - Zimmer Biomet is a global leader in medical technology with a focus on maximizing mobility and improving health through innovative products and integrated digital and robotic technologies [1][4] - The company operates in over 25 countries and has sales in more than 100 countries, showcasing its extensive global reach [2] Upcoming Events - Zimmer Biomet management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET) [3] - A live webcast of the presentation will be available on the company's Investor Relations website, with an archived replay following the conference [3]

WARSAW, Ind., Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30, 2024. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a com ...

Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration ("FDA") 510(k) clearance for the OsseoFit Stemless Shoulder System for total shoulder replacement. The system is designed to match the natural humeral (upper shoulder bone) anatomy to optimize anatomical fit while maximizing the preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company's expansive total shoulder portfolio. The company plans to launch the system commercially in the first quarter of ...

Company Developments - Zimmer Biomet Holdings Inc (ZBH) received FDA 510(k) clearance for its Persona SoluTion PPS Femur, a total knee implant component designed for patients with sensitivities to bone cement and/or metal [1] - The company expects to commercially launch Persona SoluTion PPS Femur in the United States in Q1 2025 [1] - ZBH recently received FDA Premarket Approval Application Supplement approval for the Oxford Cementless Partial Knee, making it the only FDA-approved cementless partial knee implant in the United States [8] Product Details - Persona SoluTion PPS Femur combines cementless fixation with PPS coating, providing initial scratch fit stability and supporting biological fixation through bony growth [5] - The implant minimizes common metal sensitizers by combining with Persona OsseoTi tibia and Vivacit-E Highly Crosslinked Polyethylene (HXLPE) [6] - The implant is made of Tivanium (Ti-6Al-4V) alloy with over 17 years of clinical use, treated with the Ti-Nidium Surface Hardening Process [6] Market Performance - ZBH shares moved 0.1% lower to $110.62 following the announcement [2] - The company has a market capitalization of $22.09 billion [3] - ZBH shares have lost 4.5% in the past year, compared to the industry's 21% growth [9] Financial Performance - ZBH's earnings surpassed estimates in three of the trailing four quarters, with an average surprise of 1.76% [3] Industry Outlook - The global knee replacement market is expected to reach $16.99 billion by 2031, growing at a CAGR of 5.67% during 2024-2031 [7] - Key growth drivers include rising incidence of osteoarthritis and increasing demand for joint replacement surgeries [7]

Zimmer Biomet Holdings, Inc. (ZBH) recently received Food and Drug Administration (“FDA”) Premarket Approval Application (“PMA”) Supplement approval for the Oxford Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (“IDE”) study and non-clinical testing for cementless partial knee replacement (“PKR”).With this, Oxford Cementless Partial Knee becomes the only FDA-approved cementless partial knee implant in the United States. The latest FDA ...

Core Viewpoint - Zimmer Biomet Holdings, Inc. has received the CE Mark for its Persona® Revision Knee System, enhancing its commitment to personalized medical solutions for revision knee arthroplasty [1][2]. Group 1: Product Launch and Features - The Persona Revision Knee System is designed to provide a personalized fit and optimized function for patients undergoing revision knee surgery, featuring modular components for intraoperative flexibility [3][4]. - The system incorporates Zimmer Biomet's proprietary Trabecular Metal™ Technology, which supports long-term bone in-growth and improves implant fixation [3]. - The Persona Revision Knee is positioned as a leading product in the over $700 million U.S. knee revision market, streamlining the revision surgery process and improving precision [4]. Group 2: Company Mission and Vision - The launch of the Persona Revision Knee System aligns with Zimmer Biomet's mission to alleviate pain and enhance the quality of life for patients globally through innovative solutions [5]. - With over 90 years of experience, Zimmer Biomet aims to deliver high-quality medical technology solutions, leveraging data analytics and artificial intelligence to transform patient experiences [6][7].

Core Viewpoint - Zimmer Biomet's strategic product launches and stabilizing market trends enhance confidence in the stock, despite macroeconomic uncertainties impacting the bottom line [1] Factors Driving ZBH's Share Price - Zimmer Biomet is gaining strong market share in reconstructive knees and hips across key geographies, with revenues growing mid-single digits for 11 consecutive quarters [2] - The international business exceeded sales expectations in Q3 2024, driven by strong demand in reconstructive knees, hips, and S.E.T. categories [2] - The knee business grew 10% internationally in the quarter, despite challenges from ERP system implementation [3] - Upcoming product launches, such as the Oxford Partial cementless Knee in 2025, are expected to capture 60% of the European market [3] - Anticipated launches of Z1 HAMMR and Navigation products are expected to drive market share in hips [3] - The company is focusing on the ROSA Robotic Platform combined with the Persona cementless Knee, aiming to increase robotics and cementless penetration from 20% to 50%-60% [5] Factors Affecting ZBH's Growth - Industry-wide staffing shortages and supply chain issues are negatively impacting growth [8] - Geopolitical complications and high interest rates are affecting raw material and labor costs, particularly in the dental treatment space [8] - Challenges in the hip category due to headwinds in Russia are impacting international business [8] - Reimbursement headwinds in the Restorative Therapies business are creating challenges within the S.E.T. category [8] - Acute supply challenges in Sports and Trauma are also pressuring revenues and operating profit [8] Financial Performance - In Q3, Zimmer Biomet experienced a 3.9% increase in cost of products sold and a 3.1% rise in selling, general, and administrative expenses [9] - Adjusted gross margin contracted by 34 basis points, while adjusted operating margin contracted by 18 basis points [9] - Foreign exchange fluctuations negatively impacted net sales by 0.1% in Q3 2024, with an expected adverse impact of 75 basis points for the full year [10]